Skip to Content

Xelpros (latanoprost ophthalmic) Disease Interactions

There are 5 disease interactions with Xelpros (latanoprost ophthalmic):

Major

Latanoprost (applies to Xelpros) herpes simplex

Major Potential Hazard, Moderate plausibility. Applicable conditions: Ocular Herpes Simplex

Latanoprost should be used with caution in patients with a history of herpetic keratitis and it should be avoided in cases of active simplex keratitis because of the risk of reactivation and inflammation.

Moderate

Latanoprost (applies to Xelpros) respiratory disorders

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Impairment

Latanoprost should be used with caution in patients with respiratory disorders as there have been reported post marketing cases of asthma and exacerbation of asthma, and dyspnea.

Moderate

Ophthalmic PG analogues (applies to Xelpros) macular edema

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Pseudophakia, Retinal Disorder

Macular edema, including cystoid macular edema, has been reported during treatment with ophthalmic prostaglandin analogues. Most cases occurred in patients with aphakia, pseudophakia with a torn posterior lens capsule, or known risk factors for macular edema (e.g., posterior uveitis, certain retinal disorders). Therapy with ophthalmic prostaglandin analogues should be administered cautiously in these patients.

References

  1. "Product Information. Lumigan (bimatoprost ophthalmic)" Allergan Inc, Irvine, CA.
  2. "Product Information. Xalatan (latanoprost ophthalmic)." Pharmacia and Upjohn, Kalamazoo, MI.
  3. "Product Information. Travatan (travoprost ophthalmic)" Alcon Laboratories Inc, Fort Worth, TX.
Moderate

Ophthalmic PG analogues (applies to Xelpros) uveitis

Moderate Potential Hazard, Moderate plausibility.

Bimatoprost, latanoprost, and travoprost are synthetic prostaglandin analogues. Theoretically, these agents may mimic endogenous prostaglandins and mediate ocular inflammatory responses. In clinical trials, uveitis and iritis have been reported rarely. Therapy with ophthalmic prostaglandin analogues should be administered cautiously in patients with active intraocular inflammation.

References

  1. "Product Information. Travatan (travoprost ophthalmic)" Alcon Laboratories Inc, Fort Worth, TX.
  2. "Product Information. Xalatan (latanoprost ophthalmic)." Pharmacia and Upjohn, Kalamazoo, MI.
  3. "Product Information. Lumigan (bimatoprost ophthalmic)" Allergan Inc, Irvine, CA.
Moderate

Ophthalmic PGF2a analogues- renal/liver disease

Moderate Potential Hazard, Low plausibility. Applicable conditions: Renal Dysfunction

Prostaglandin F2-alpha analogues are hydrolyzed by esterases in the cornea to their corresponding active free acid form, which is absorbed systemically and metabolized by the liver via fatty acid beta-oxidation, then eliminated by the kidney. These agents have not been adequately studied in the treatment of patients with impaired renal and/or hepatic function. Therapy with ophthalmic prostaglandin F2-alpha analogues should be administered cautiously in such patients.

References

  1. "Product Information. Xalatan (latanoprost ophthalmic)." Pharmacia and Upjohn, Kalamazoo, MI.
  2. "Product Information. Travatan (travoprost ophthalmic)" Alcon Laboratories Inc, Fort Worth, TX.

Xelpros (latanoprost ophthalmic) drug interactions

There are 6 drug interactions with Xelpros (latanoprost ophthalmic)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.